WO2015082376A3 - Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for the treatment of cancer - Google Patents
Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for the treatment of cancer Download PDFInfo
- Publication number
- WO2015082376A3 WO2015082376A3 PCT/EP2014/076051 EP2014076051W WO2015082376A3 WO 2015082376 A3 WO2015082376 A3 WO 2015082376A3 EP 2014076051 W EP2014076051 W EP 2014076051W WO 2015082376 A3 WO2015082376 A3 WO 2015082376A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- dihydroimidazo
- quinazolines
- cancer
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The present invention relates to 2,3-dihydroimidazo(1,2-c)quinazoline derivatives as inhibitors of P13K kinase for the treatment or prophylaxis of a disease, particularly for the treatment of cancers and their metastases.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13195567.6 | 2013-12-03 | ||
EP13195567 | 2013-12-03 | ||
EP14163752 | 2014-04-07 | ||
EP14163752.0 | 2014-04-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015082376A2 WO2015082376A2 (en) | 2015-06-11 |
WO2015082376A3 true WO2015082376A3 (en) | 2015-07-30 |
Family
ID=51999440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/076051 WO2015082376A2 (en) | 2013-12-03 | 2014-12-01 | Use of pi3k-inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015082376A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180104597A (en) | 2015-11-07 | 2018-09-21 | 멀티비르 인코포레이티드 | Compositions comprising tumor suppressor gene therapy and immune blockade for cancer therapy |
US20200009203A1 (en) | 2016-12-12 | 2020-01-09 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
MX2020004666A (en) | 2017-11-17 | 2022-01-26 | Cellix Bio Private Ltd | Compositions and methods for the treatment of eye disorders. |
KR20200135986A (en) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | Methods and compositions for cancer treatment comprising tumor suppressor gene therapy and CD122/CD132 agonists |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
WO2012062743A1 (en) * | 2010-11-11 | 2012-05-18 | Bayer Pharma Aktiengesellschaft | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines |
WO2012062748A1 (en) * | 2010-11-11 | 2012-05-18 | Bayer Pharma Aktiengesellschaft | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
WO2012136549A1 (en) * | 2011-04-05 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
US20130184270A1 (en) * | 2010-04-16 | 2013-07-18 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
WO2014166820A1 (en) * | 2013-04-08 | 2014-10-16 | Bayer Pharma Aktiengesllschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
-
2014
- 2014-12-01 WO PCT/EP2014/076051 patent/WO2015082376A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
US20130184270A1 (en) * | 2010-04-16 | 2013-07-18 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
WO2012062743A1 (en) * | 2010-11-11 | 2012-05-18 | Bayer Pharma Aktiengesellschaft | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines |
WO2012062748A1 (en) * | 2010-11-11 | 2012-05-18 | Bayer Pharma Aktiengesellschaft | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
WO2012136549A1 (en) * | 2011-04-05 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
WO2014166820A1 (en) * | 2013-04-08 | 2014-10-16 | Bayer Pharma Aktiengesllschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
Non-Patent Citations (4)
Title |
---|
DIMITRIOS ZARDAVAS ET AL: "Emerging targeted agents in metastatic breast cancer", NATURE REVIEWS CLINICAL ONCOLOGY, NATURE, NY, US, vol. 10, 1 April 2013 (2013-04-01), pages 191 - 210, XP009174469, ISSN: 1759-4774 * |
N. LIU ET AL: "BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110 and p110 Activities in Tumor Cell Lines and Xenograft Models", MOLECULAR CANCER THERAPEUTICS, vol. 12, no. 11, 29 October 2013 (2013-10-29), US, pages 2319 - 2330, XP055121310, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-12-0993-T * |
SETH A. WANDER ET AL: "PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy", BREAST CANCER RESEARCH AND TREATMENT, vol. 138, no. 2, 21 February 2013 (2013-02-21), pages 369 - 381, XP055164167, ISSN: 0167-6806, DOI: 10.1007/s10549-012-2389-6 * |
YAN XIE ET AL: "Identification of upregulated phosphoinositide 3-kinase [gamma] as a target to suppress breast cancer cell migration and invasion", BIOCHEMICAL PHARMACOLOGY, vol. 85, no. 10, 1 May 2013 (2013-05-01), pages 1454 - 1462, XP055164166, ISSN: 0006-2952, DOI: 10.1016/j.bcp.2013.03.001 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015082376A2 (en) | 2015-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291000A (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer | |
HRP20190152T1 (en) | Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak) | |
EP3399968B8 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
NZ718190A (en) | Substituted quinazolines for inhibiting kinase activity | |
EP3246328A4 (en) | Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof | |
WO2014172644A3 (en) | Bicyclic heterocycles as fgfr inhibitors | |
HRP20150692T8 (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases | |
SI3808749T1 (en) | Pyrazolo(1,5-a)pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases | |
MX2016002544A (en) | Compounds useful as immunomodulators. | |
PH12016501232A1 (en) | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | |
JOP20140141B1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas | |
MX2015014234A (en) | 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors. | |
WO2015082376A3 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for the treatment of cancer | |
MX2012013527A (en) | Fused quinazoline derivatives and uses thereof. | |
CR20150659A (en) | DERIVATIVES OF PRODUCTION OF SUBSTITUTED TRIAZOLPIRIDINES | |
EP3071204A4 (en) | Quinazoline derivatives as tam family kinase inhibitors | |
WO2014160177A3 (en) | Quinazoline inhibitors of pi3k | |
CL2014001265A1 (en) | Compounds derived from uracil, axl and c-met kinase inhibitors, useful in the treatment of cancer. | |
AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14805293 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14805293 Country of ref document: EP Kind code of ref document: A2 |